Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology.
Mayinglong Pharmaceutical Group Co. Ltd. has reported new 5-HT4 receptor agonists that are potentially useful for the treatment of gastroesophageal reflux disease, constipation, irritable bowel syndrome, dyspepsia, delayed gastric emptying (gastroparesis), intestinal pseudo-obstruction, diabetic gastroparesis and postoperative Ileus.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has identified new molecular glue degrader compounds acting as proto-oncogene Vav (VAV1)/protein cereblon (CRBN) interaction inducers for degradation of VAV1 reported to be useful for the treatment of inflammatory bowel disease.
Spyre Therapeutics Inc. is off to a good start in its goal to create the best combination therapy for inflammatory bowel disease, a group of chronic, relapsing autoimmune conditions of the digestive tract that encompasses Crohn’s disease and ulcerative colitis. The Waltham, Mass.-based company estimates the market for IBD is currently at approximately $25 billion but will jump to around $40 billion in 2030.
The development of glucagon-like peptide 1 receptor (GLP-1R) agonists, such as semaglutide and tirzepatide, has been a game changer in the clinical management of overweight and obesity, but there is interpersonal variability in efficacy of these medications for weight loss, as well as in the incidence of undesired side effects. Investigators from the 23andMe Research Institute have shed some light on how variations in the GLP-1R and GIP receptor (GIPR) genes impact their effectiveness and the occurrence of side effects.
The tumor necrosis factor (TNF)-α-induced protein 8-like 2 (TIPE2), predominantly expressed in bone marrow-derived cells or lymphoid tissues, is an essential regulator of immune homeostasis. TIPE2 acts as a key negative modulator of inflammatory signaling through the suppression of toll-like receptor (TLR) activity, with TIPE2-deficient mice exhibiting spontaneous systemic inflammation and premature death.
Proqr Therapeutics NV has highlighted the continued progression and expansion of its early-stage pipeline of RNA editing therapies, including programs in cholestatic diseases, Hurler syndrome, metabolic dysfunction-associated steatohepatitis and Rett syndrome.
The U.S. path forward is narrowing for Vanda Pharmaceuticals Inc.’s tradipitant as a treatment for gastroparesis, a serious disorder for which there’s been no new treatment in several decades.
In recent work, researchers from Shanghai Jiaotong University School of Medicine and Shanghai Colorectal Cancer Research Center reported that the transcription factor hematopoietically expressed homeobox (HHEX) promotes tumorigenesis in colitis-associated colorectal cancer. In a new paper, the team aimed to further characterize the biological function and potentially dysregulated mechanisms of HHEX during intestinal inflammation, which remained largely unexplored.
RSS
